Yohanka Martinez-Gzegozewska , Lynn Rasmussen , N. Miranda Nebane , Sara McKellip , Dee Radzieta , Anna Manuvakhova , Andrew J. Reece , Pedro Ruiz , Sixue Zhang , Omar Moukha-Chafiq , Melinda Sosa , Corinne Augelli-Szafran , Richard Whitley , Robert Bostwick , Paige Vinson
{"title":"High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay","authors":"Yohanka Martinez-Gzegozewska , Lynn Rasmussen , N. Miranda Nebane , Sara McKellip , Dee Radzieta , Anna Manuvakhova , Andrew J. Reece , Pedro Ruiz , Sixue Zhang , Omar Moukha-Chafiq , Melinda Sosa , Corinne Augelli-Szafran , Richard Whitley , Robert Bostwick , Paige Vinson","doi":"10.1016/j.antiviral.2025.106209","DOIUrl":null,"url":null,"abstract":"<div><div>A highly sensitive cell-based imaging assay has been used to screen a 200,000 compounds library for potential influenza antivirals. Compounds were screened at a concentration of 10 μM against the influenza strain A/Udorn/72 (H3N2) and the duplex capability of the assay was taken advantage of to select compounds with no or low cytotoxicity. The assay was also used for confirmation in concentration-response of the active compounds. In the set of confirmed hits, three major structural clusters, 23 minor clusters and 86 singletons were identified. Further evaluation of anti-influenza activity was performed for two additional influenza strains of the H1N1 subtype, A/WSN/33 and A/California/07/09. Three compounds from cluster A, SRI-44211, SRI-44215 and SRI-44221 showed selectivity indices for the pandemic strain A/California/07/09 in the range of 54.3–252, providing evidence that the core structure of cluster A could play a relevant role in their inhibitory potency and may serve as a starting point for future hit-to-lead optimization efforts.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"240 ","pages":"Article 106209"},"PeriodicalIF":4.5000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0166354225001354","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
A highly sensitive cell-based imaging assay has been used to screen a 200,000 compounds library for potential influenza antivirals. Compounds were screened at a concentration of 10 μM against the influenza strain A/Udorn/72 (H3N2) and the duplex capability of the assay was taken advantage of to select compounds with no or low cytotoxicity. The assay was also used for confirmation in concentration-response of the active compounds. In the set of confirmed hits, three major structural clusters, 23 minor clusters and 86 singletons were identified. Further evaluation of anti-influenza activity was performed for two additional influenza strains of the H1N1 subtype, A/WSN/33 and A/California/07/09. Three compounds from cluster A, SRI-44211, SRI-44215 and SRI-44221 showed selectivity indices for the pandemic strain A/California/07/09 in the range of 54.3–252, providing evidence that the core structure of cluster A could play a relevant role in their inhibitory potency and may serve as a starting point for future hit-to-lead optimization efforts.
期刊介绍:
Antiviral Research is a journal that focuses on various aspects of controlling viral infections in both humans and animals. It is a platform for publishing research reports, short communications, review articles, and commentaries. The journal covers a wide range of topics including antiviral drugs, antibodies, and host-response modifiers. These topics encompass their synthesis, in vitro and in vivo testing, as well as mechanisms of action. Additionally, the journal also publishes studies on the development of new or improved vaccines against viral infections in humans. It delves into assessing the safety of drugs and vaccines, tracking the evolution of drug or vaccine-resistant viruses, and developing effective countermeasures. Another area of interest includes the identification and validation of new drug targets. The journal further explores laboratory animal models of viral diseases, investigates the pathogenesis of viral diseases, and examines the mechanisms by which viruses avoid host immune responses.